NCT03625388已完成2 期
Randomized, Open-Label, Phase II, Multicenter, Multi-Country Study to Evaluate Safety and Efficacy of Dasatinib 50 mg in First-Line Treatment of Early Chronic Phase Chronic Myeloid Leukemia
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 56
- 试验地点
- 5
- 主要终点
- Proportion of patients who achieve and maintain MMR at 12 months using RQ-PCR test
研究概览
简要总结
The purpose of this multicenter randomized study is to compare efficacy and safety of dasatinib 50 mg once daily and dasatinib 100 mg once daily in patients with early chronic phase (CP) chronic myeloid leukemia (CML)
详细描述
A multicenter, prospective, open-label, randomized Phase II study to compare efficacy by measuring rates of major molecular response (MMR) at 12 months in patients with Ph+ chronic phase (CP) chronic myeloid leukemia (CML) randomized to receive either dasatinib 50 mg QD or dasatinib 100 mg QD. Approximately 100 patients are expected to be randomized. The duration of patient participation will be 18 months
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years.
- •Diagnosis of Ph+ or BCR-ABL positive CML in early CP (i.e. time from diagnosis <12 months). Except for hydroxyurea and/or 1-2 doses of cytarabine (up to 6g/m2 total), patients must have received no or minimal prior therapy, defined as 30 days of prior approved tyrosine kinase inhibitor (TKI).
- •Clonal evolution defined as the presence of additional chromosomal abnormalities other than the Ph-chromosome has been historically included as a criterion of accelerated phase (AP). However, patients with clonal evolution as the only criterion of AP have a significantly better prognosis, and when present at diagnosis may not impact the prognosis at all. Thus, patients with clonal evolution and no other criteria for AP will be eligible for this study.
- •ECOG performance of 0-
- •Adequate end organ function defined as the following: total bilirubin <1.5x ULN (unless secondary to Gilbert's disease, in which case it should be <2.5x ULN), SGPT <2.5x ULN, creatinine <1.5x ULN.
- •Patients must sign an informed consent form (ICF) indicating they are aware of the investigational nature of this study, in keeping with the policies of the hospital
排除标准
- •NYHA cardiac class 3-4 heart disease
- •Cardiac symptoms - Patients meeting the following criteria are not eligible unless cleared by a cardiologist:
- •Uncontrolled angina within 3 months
- •Diagnosed or suspected congenital long QT syndrome
- •Any history of clinically significant ventricular arrhythmias (such as ventricular tachycardia, ventricular fibrillation, or torsades de pointes)
- •Prolonged QTc interval on pre-entry electrocardiogram (>460 msec)
- •History of significant bleeding disorder unrelated to cancer including:
- •Diagnosed congenital bleeding disorders (e.g. Von Willebrand's disease)
- •Diagnosed acquired bleeding disorder within one year (e.g. acquired anti-factor VIII antibodies)
- •Isolated thrombocytopenia without recurrent bleeding episodes shall be considered eligible for study entry
- •Patients with active uncontrolled psychiatric disorders including: psychosis, major depression, and bipolar disorders
- •Women of pregnancy potential must practice an effective method of birth control, unless otherwise instructed, during the course of the study in a manner such that risk of failure is minimized
- •Prior to study enrollment, women of childbearing potential (WOCBP) must be advised of the importance of avoiding pregnancy during study participation and the potential risk factors for an unintentional pregnancy
- •Postmenopausal women must be amenorrheic for at least 12 months to be considered of non-childbearing potential
- •Women must continue birth control for the duration of the study and at least 3 months after the last dose of study drug
- •Pregnant or breast-feeding women are excluded
- •a. All WOCBP must have a negative pregnancy test prior to first receiving the study drug. If the pregnancy test is positive, the patient must not receive the study drug and must not be enrolled in the study.
- •Patients in late chronic phase (i.e. time from diagnosis to treatment >12 months), accelerated phase (except as noted in inclusion criteria 2) or blast phase are excluded.
研究组 & 干预措施
Dasatinib 50 mg
Other
Dasatinib 50 mg orally once daily
干预措施: Dasatinib (Drug)
Dasatinib 100 mg
Other
Dasatinib 100 mg orally once daily
干预措施: Dasatinib (Drug)
结局指标
主要结局
Proportion of patients who achieve and maintain MMR at 12 months using RQ-PCR test
时间窗: 12 months
Major molecular response (MMR) is defined as BCR-ABL1 ≤ 0.1%
次要结局
- Event free survival (EFS)(18 months)
- Proportion of patients with MR 4.5 at 18 months(18 months)
- Frequency of not taking the medications as prescribed(18 months)
- Incidence of adverse events (AEs) and serious adverse events (SAEs) to dasatinib(18 months)
- Overall survival(18 months)
- Blastic phase (BP) transformation(18 months)
- Transformation free survival (TFS) in eligible patients randomized to dasatinib 50 mg or dasatinib 100 mg treatment arms(18 months)
- Proportion of patients with Complete cytogenetic response (CCyR) at 12 months(12 months)
- Health-Related Quality of Life (HRQoL): EORTC QOLCML24(18 months)
研究者
研究点 (5)
Loading locations...
相似试验
已完成
1 期
Dasatinib (Sprycel™) in Patients With Newly Diagnosed Core Binding Factor (CBF) Acute Myeloid Leukemia (AML)Acute Myeloid Leukemia (AML)NCT00850382University of Ulm89
已完成
2 期
Study of Dasatinib to Treat Philadelphia Positive Acute Lymphoblastic LeukemiaLeukemia, Lymphoblastic, Acute, Philadelphia-PositiveNCT01310010Grupo Espanol de trasplantes hematopoyeticos y terapia celular30
Unknown
2 期
Evaluation of Response of Dasatinib to Treat MastocytosisSystemic MastocytosisNCT00979160Federico II University30
Unknown
不适用
A Clinical Trial Evaluating the Efficacy and Safety of Dasatinib in Refractory Metastatic GISTGastrointestinal Stromal TumorNCT02776878Peking University Cancer Hospital & Institute57
已完成
4 期
A Study of Dasatinib as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia (CML-CP)Chronic Myelogenous Leukemia - Chronic PhaseNCT04925141Chia Tai Tianqing Pharmaceutical Group Co., Ltd.62